NK-1 Drug Fills Motion Sickness Gap - Poll - MDSpire

NK-1 Drug Fills Motion Sickness Gap

Tradipitant demonstrates 50% to 70% risk reduction for vomiting incidence during motion exposure in phase 3 trials.

  • By

  • Kerri Miller

  • January 2, 2026

  • 3 min

Share

Original Source(s)

NK-1 Drug Fills Motion Sickness Gap

  • by Kerri Miller

  • January 2, 2026

Related Content

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Meta-analysis of the therapeutic effects of traumatic BPPV and idiopathic BPPV

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.